A Hybrid Secure Cloud Platform Maintenance Based on Improved Attribute-Based Encryption Strategies

In the modern era, Cloud Platforms are the most needed port to maintain documents remotely with proper security norms. The concept of cloud environments is similar to the network channel. Still, the Cloud is considered the refined form of network, in which the data can easily be stored into the server without any range restrictions. The data maintained into the remote server needs a high-security feature, and the processing power of data should be high to retrieve the data back from the respective server. In the past, there were several security schemes available to protect the remote cloud server reasonably. However, the attack possibilities over the cloud platform remain; only all the researchers continuously work on this platform without any delay. This paper introduces a hybrid data security scheme called the Improved Attribute-Based Encryption Scheme (IABES). This IABES combines two powerful data security algorithms: Advanced Encryption Standard (AES) and Attribute-Based Encryption (ABE) algorithm. These two algorithms are combined to provide massive support to the proposed approach of data maintenance over the remote cloud server with high-end security norms. This hybrid data security algorithm assures the data cannot be attacked over the server by the attacker or intruder in any case because of its robustness. The essential generation process generates a credential for the users. It cannot be identified or visible to anyone as well as the generated certificates cannot be extracted even if the corresponding user forgets the credentials. The only way to get back the certification is resetting the credential. The obtained results prove the accuracy level of the proposed cypher security schemes compared with the regular cloud security management scheme, and the proposed algorithm essential generation process is unique. No one can guess or acquire it. Even the person may be the service provider or server administrator. For all, the proposed system assures data maintenance over the cloud platform with a high level of security and robustness in Quality of Service

Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial

Background/Aims: Minimal hepatic encephalopathy (MHE) implies subtle impairment of cognitive functions in the absence of features of overt encephalopathy. We aimed to determine the prevalence of MHE in patients with liver cirrhosis and to find out the effect of rifaximin, probiotics, and l-ornithine l-aspartate (LOLA) individually in reversal of MHE by comparing it with placebo group. Patients and Methods: This study was carried out in two phases. Phase I included the recruitment of 250 apparently healthy controls and extraction of normative data utilizing three neuropsychometric tests (NPTs) and critical flicker frequency (CFF) test. Phase II consisted of screening and recruitment of patients of MHE followed by drugs trial. A total of 317 cirrhotics were screened; 111 were excluded and the remaining 206 cirrhotics were screened for MHE using NPTs and/or CFF test. Of these, 124 patients with MHE were randomized to receive LOLA (n = 31), rifaximin (n = 31), probiotics (n = 32), for 2 months and were compared with patients who were given placebo (n = 30). Results: Out of 206 cirrhotics, 124 (60.19%) had MHE. Among these 124 MHE patients, 87 (70.16%) patients had CFF <39Hz, 112 (90.32%) patients with MHE had two or more abnormal NPTs, and 75 (60.48%) patients had abnormality on both the CFF values and more than two abnormal NPTs. Intention-to-treat analysis showed the number of patients who improved after giving treatment were 67.7% (21/31), 70.9% (22/31), 50% (16/32), and 30% (9/30) for LOLA, rifaximin, probiotics, and placebo, respectively. CFF scores and improvement in psychometric tests after treatment were significantly higher (P < 0.05) for LOLA, rifaximin, and probiotics as compared with placebo group. Conclusions: Prevalence of MHE is high in patients with cirrhosis of liver. Rifaximin, LOLA, and probiotics are better than giving placebo in patients with MHE